Production (Stage)
Ensysce Biosciences, Inc.
ENSC
$2.07
-$0.07-3.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 256.36% | 133.58% | 40.41% | -51.96% | -35.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 256.36% | 133.58% | 40.41% | -51.96% | -35.55% |
| Cost of Revenue | 26.72% | -4.85% | -52.11% | -59.87% | -64.11% |
| Gross Profit | 56.42% | 62.49% | 85.80% | 61.91% | 69.07% |
| SG&A Expenses | -8.18% | -11.95% | -0.67% | -6.26% | -18.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.34% | -7.79% | -36.55% | -45.09% | -52.43% |
| Operating Income | 31.45% | 37.21% | 54.16% | 43.89% | 54.51% |
| Income Before Tax | 40.99% | 24.83% | 37.08% | 42.93% | 54.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.99% | 24.83% | 37.08% | 42.93% | 54.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -99.24% | -- | -88.67% | -76.20% |
| Net Income | 40.95% | 24.74% | 37.09% | 42.88% | 54.58% |
| EBIT | 31.45% | 37.21% | 54.16% | 43.89% | 54.51% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 87.48% | 82.30% | 91.72% | 96.65% | 95.69% |
| Normalized Basic EPS | 87.47% | 82.73% | 91.25% | 97.06% | 96.21% |
| EPS Diluted | 87.48% | 82.30% | 91.72% | 96.65% | 95.69% |
| Normalized Diluted EPS | 87.47% | 82.73% | 91.25% | 97.06% | 96.21% |
| Average Basic Shares Outstanding | 310.92% | 350.24% | 309.45% | 445.81% | 832.41% |
| Average Diluted Shares Outstanding | 310.92% | 350.24% | 309.45% | 445.81% | 832.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |